Gary Evans
Internal Medicine · Bowie, TXNPI 1346200904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $403 and has fallen 50.8% since, to $198 in 2023.
Across 90 payments — averaging $15.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$210
- AbbVie$136
- Bayer$129
- Novo Nordisk$113
- Dexcom, Inc.$80
- Novartis$64
- plus $687 from 24 others
What the payments were for
- Food & beverage$1,40099%
- Entertainment$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 15 | $210 |
| AbbVie(2 entities) | 7 | $136 |
| Bayer | 9 | $129 |
| Novo Nordisk | 9 | $113 |
| Dexcom, Inc. | 5 | $80 |
| Novartis | 4 | $64 |
| Stryker | 1 | $64 |
| Mylan Specialty L.p. | 4 | $61 |
| GSK | 3 | $56 |
| Sanofi-aventis U.S. LLC | 4 | $55 |
| Astellas Pharma US Inc | 3 | $48 |
| Eisai Inc. | 2 | $42 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Lilly USA, LLC | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Amgen | 2 | $27 |
| Philips North America LLC | 2 | $27 |
| Merck | 2 | $26 |
| Insulet Corporation | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Optos, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $12 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
| MDD US Operations, LLC | 1 | $12 |
| Medtronic | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,419 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbamazepine | 12 | $766 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bowie
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.